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Abstract E. multilocularis (Em) is the etiologic agent of alve-
olar echinococcosis (AE), a severe and potentially fatal disease,
primarily affecting the liver of and occurring in aberrant inter-
mediate hosts, e.g., humans and non-human primates. Due to
increasing numbers of spontaneous cases of AE in the Old
World monkey colonies of the German Primate Center, the
question arose as to whether vaccination of non-human
primates may represent a useful prophylactic approach. In this
pilot study, the recombinant antigen Em14-3-3, which has
provided a 97 % protection against E. multilocularis challenge
infection in rodent models, was used for the first time to
immunize rhesus macaques. In order to increase immunogenic-
ity, the antigen was formulated with different adjuvants
including Quil A®, aluminum hydroxide (alum), and muramyl
dipeptide (MDP). Also, different vaccination regimens were
tested. All vaccinated animals developed antigen-specific
antibodies. While Quil A® induced a local adverse reaction,
alum proved to be the most potent adjuvant in terms of induced
antibody levels, longevity as well as tolerability. In conclusion,
our pilot study demonstrated that recombinant Em14-3-3 is safe
and immunogenic in rhesus monkeys. As a next step, efficacy
of the vaccination remains to be explored.
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Introduction
Alveolar echinococcosis (AE), caused by the metacestode
stage of the fox tapeworm Echinococcus (E.) multilocularis,
represents one of the most severe parasitic zoonoses in the
Northern hemisphere. The tapeworm is usually perpetuated
in a sylvatic life cycle which includes foxes (Vulpes vulpes)
as final hosts and various rodent species as intermediate hosts
(Eckert and Deplazes 2004). However, humans and non-
human primates may also acquire the infection through
accidental ingestion of E. multilocularis eggs (Ammann and
Eckert 1996; Brack et al. 1997; Bacciarini et al. 2004; Tappe
et al. 2007). In these aberrant intermediate hosts, AE is
characterized by a chronically progressive and malignant liver
disease which gradually affects adjacent organs and is usually
fatal without timely initiation of an adequate therapy
(Ammann and Eckert 1996; Kern et al. 2006; Tappe et al.
2007). In the Old World monkey breeding colony of the
German Primate Center, a total of 23 cases of spontaneous
AE have occurred between 1994 and 2014, affecting 14
cynomolgus macaques (Macaca fascicularis) and nine rhesus
monkeys (Macaca mulatta). Diseased animals had to be
euthanized due to severe metacestode infiltration of the liver
and other organs. Serological screening revealed a high
prevalence of anti-E. multilocularis antibodies, especially
among cynomolgus macaques, raising concerns about new
cases and reflecting a continuous infection pressure.
It has long been recognized that specific immune reactions
of the intermediate host are capable of killing the oncosphere
stages of various cestode species. In contrast, neither intestinal
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adult stages of E. multilocularis nor larvae, which are
surrounded by a protective laminated layer by day 14 post
infection (p.i.), can be eliminated by the immune system
(Craig 2003; Gottstein 2005). Therefore, the objective of a
vaccination against AE is to induce a protective immune re-
sponse against an establishing oncosphere at an early stage of
infection (Gottstein 2005). In different rodent models for
cestode infections, immunization with recombinant proteins
provided an effective protection against subsequent challenge
infection (Ito et al. 1991; Manoutcharian et al. 1996; Müller-
Schollenberger et al. 2001). One of themost promising antigens
for the vaccination of intermediate hosts against the fox
tapeworm is the protein Em14-3-3. The overexpression of this
protein in the germinal layer of E. multilocularis is considered
to lead to excessive proliferation of the metacestode (Siles-
Lucas et al. 1998; Siles-Lucas et al. 2001; Siles-Lucas et al.
2003). Parenteral vaccination of BALB/c mice with recombi-
nant Em14-3-3 (E14t) provided 97 % protection against
primary (oral) challenge infection with 2000 E. multilocularis
eggs (Siles-Lucas et al. 2003).
Considering the ongoing problem of AE at the German
Primate Center, the question arose if vaccination of the non-
human primates represents a useful prophylactic approach to
prevent infection with the parasite. Therefore, as a first step,
the aim of this pilot study was to investigate whether vaccina-
tion with the recombinant antigen Em14-3-3 is safe and im-
munogenic in rhesus monkeys.
Materials and methods
Animals used in the study
The study included six 17–21-year-old female rhesus monkeys
(Macaca mulatta) from the breeding colony of the German
Primate Center, Goettingen, Germany. Care and housing condi-
tions of the animals complied with the regulations of the
European Parliament and the Council Directive on the protection
of animals used for scientific purposes (2010/63/EU). All proce-
dures performed in studies involving animals were in accordance
with the ethical standards of the German Primate Center.
Collection of blood samples for serological testing, physical
examination, and administration of the vaccines were carried
out under anaesthesia with a mixture of 5 mg ketamine hydro-
chloride (Ketavet® Pfizer, Karlsruhe, Germany), 1 mg xylazin
hydrochloride (Rompun® TS, Bayer, Leverkusen, Germany),
and 0.01 mg atropine sulphate (Atropinsulfat, Dr. Franz Köhler
Chemie GmbH, Bensheim, Germany) per kg body weight.
Pre- and post-vaccination serology
Serological testing of all six animals was carried out prior to
vaccination by means of Em2-ELISA (Bacciarini et al. 2005;
Rehmann et al. 2005; Gottstein et al. 1993) and Western blot
(Mueller et al. 2007) for antibodies against E. multilocularis,
to rule out any potential contact with the parasite for these
animals before starting experiments. For post-vaccination
monitoring of vaccine-specific immune responses, a rec14-
3-3-ELISAwas performed. This ELISAwas basically carried
out as reported earlier for a mouse study (Siles-Lucas et al.
2003), except that the anti-mouse-IgG-alkaline phosphatase
conjugate was replaced by the same anti-monkey conjugate
as used for the above mentioned Em2-ELISA.
Preparation of the Em14-3-3 antigen
The recombinant E. multilocularis 14-3-3 protein used
represented 60 % (C-terminus) of the corresponding
E. multilocularis full-length metacestode protein (Siles-Lucas
et al. 1998). Production methodology and purity level of the
recombinant 14-3-3 antigen were identical to that previously
used for mice (Siles-Lucas et al. 2003).
Vaccination schedules
Five rhesus monkeys were vaccinated with the purified
recombinant Em-14-3-3, a sixth animal served as negative
adjuvant control (Table 1). In order to evaluate the immu-
nogenicity of the antigen and the safety of the selected
adjuvant Quil A® (InvivoGen, Toulouse, France), only
one animal (13698) was initially vaccinated. The vaccina-
tion schedule comprised one initial and two subsequent
booster vaccinations on days 14 and 28. A volume of
1 ml of the vaccine was administered subcutaneously into
the upper arm.
The five remaining animals were then divided into three
groups (Table 1). For two animals, alumimium hydroxide
(alum) (Serva, Heidelberg, Germany) was selected as adju-
vant; a total volume of 0.5 ml of the vaccine was applied. In
the second group, muramyl dipeptide (MDP, N-Acetyl-
Muramyl-L-Alanyl-D-Isoglutamin; InvivoGen, San Diego,
USA) was administered as adjuvant with a total volume of
the vaccine of 1 ml. One animal received 670 μl of a mock
vaccine containing only MDP, serving as an adjuvant control.
The administration site was identical to animal 13698 for all
groups, respectively. For dilution, sterile pyrogen free 0.9 %
NaCl solution was used; the composition of the respective
vaccines is depicted in Table 1. In order to determine the
influence of the chosen interval between the initial and the
booster vaccinations on immunogenicity, a different vaccina-
tion schedule than that in animal 13698 was chosen for the
animals of group 1 and 2. Therefore, after the initial vaccina-
tion, the latter received the two booster vaccinations on days
28 and 84, respectively (Fig. 2).
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Results and discussion
All rhesus monkeys vaccinated with the recombinant Em14-
3-3 antigen developed parasite-specific antibodies, albeit at
varying levels. This observation is in line with the results of
previous experiments in mice confirming the immunogenicity
of the recombinant Em14-3-3 (Siles-Lucas et al. 2003;
Margos and Gottstein 2010). The kinetics of the antibody
levels in the five vaccinated monkeys as well as in the control
animal are shown in Figs. 1 and 2, respectively.
The first animal (13698), which received Quil A® adjuvant,
developed a focally extensive panniculitis at the injection site,
which was considered a local adverse reaction to the adjuvant.
Local inflammation following the administration of Quil A®
adjuvant, a partially purified saponin, had previously been
described, which confirmed this assumption (Kersten and
Crommelin 1995; Spickler and Roth 2003; Sun et al. 2009).
Although Quil A has been applied in vaccinations of macaques
before (Stittelaar et al. 2002), we subsequently preferred the use
of other adjuvants instead due to the potentially irritating quality
of this adjuvant observed in one of our animals.
Compared to the animals of group 1 (alum group), the
monkeys of group 2 (MDP group) showed considerably lower
antibody levels subsequent to all three vaccinations. In the
control animal, which received adjuvant only, no seroconver-
sion was observed. In group 1, the primates remained
seropositive for 8 months after the second booster vaccination,
whereas the antibody levels in the animals of group 2 dropped
below the detection limit within two and five months, respec-
tively. Thus, the present study underlines that the selection of
the adjuvant influences not only the safety of the vaccine, but
also has a substantial impact on immunogenicity. Although
generally considered a relatively weak adjuvant with low
resulting antibody titers (Spickler and Roth 2003), alum
proved to be the most potent adjuvant in our approach. The
exact mechanism of action of alum is hitherto controversial
(Li et al. 2007; Kool et al. 2008; Mckee et al. 2009; Hutchison
et al. 2012). Therefore, it remains elusive why antibody
concentrations induced with the immune modulatory
peptidoglycane MDP were considerably lower compared to
the alum group.
In contrast to the chosen adjuvant, the impact of the
two different vaccination schedules (0–14–28 vs. 0–28–
84) on the durability of antibodies appeared to be less
distinct: although the animals of group 1 and group 2
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Fig. 1 Kinetic of the anti-Em14-3-3 antibody levels measured by rec14-
3-3 ELISA in the first vaccinated rhesus monkey (13698) following vac-
cination. The black arrows indicate the dates of the vaccinations. Serum
dilution was 1:100
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Fig. 2 Kinetic of the anti-Em-14-3-3 antibody levels in group 1- (13699
and 13700) and group 2- (13701 and 13702) vaccines and the negative
control animal pre and post vaccination. Time points of respective vacci-
nations are indicated by black arrows. Serum dilution was 1:100
Table 1 Rhesus monkeys used
for the pilot vaccination study
with recombinant Em 14-3-3 and
the compositions of the respective
vaccines
Animal No. Group Composition of vaccine
13698 Initial evaluation Quil A 250 μg, Em14-3-3 100 μg, NaCl 170 μl
13699 1 Aluma 44 μl, Em14-3-3 100 μg, NaCl 126 μl
13700 1 Alum 44 μl, Em14-3-3 100 μg, NaCl 126 μl
13701 2 MDPb 400 μl, Em14-3-3 100 μg, NaCl 270 μl
13702 2 MDP 400 μl, Em14-3-3 100 μg, NaCl 270 μl
13703 Negative control MDP 400 μl, NaCl 270 μl
a Aluminium hydroxide
bMuramyl dipeptide, N-Acetyl-Muramyl-L-Alanyl-D-Isoglutamin
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received the vaccinations at identical intervals, antibodies
in the alum group remained on a low level plateau until
the end of the study period whereas they decreased to
seronegative values in the MDP group by 4 months after
final immunisation. In contrast, antibody persistence in
the animal vaccinated with the Quil A® adjuvant was
comparable to that of the alum group. However, due to
the small group size in our pilot study, conclusions are
only valid to a certain extent.
In order to evaluate the efficacy of the vaccine, a challenge
infection or parasite exposure of the immunized rhesus
monkeys is essential. In previous studies, vaccinated mice
were challenged orally with E. multilocularis eggs (primary
infection) and intraperitoneal inoculation of metacestode
tissue (secondary infection), respectively, with a subsequent
quantitative assessment of metacestode proliferation (Müller-
Schollenberger et al. 2001; Gauci et al. 2002; Siles-Lucas et al.
2003; Margos and Gottstein 2010). The seroconversion
induced by vaccination alone is not necessarily a criterion
for the efficacy of the immunisation. Müller-Schollenberger
et al. (2001), using Salmonella typhimurium-delivered
E. multilocularis glyceraldehyde-3-phosphate dehydrogenase
(EmGAPDH) as antigen, demonstrated that vaccinated mice
were protected significantly against challenge infection,
although specific antibodies were not detectable. In contrast,
despite detection of vaccine-induced specific anti-EmGAPDH
antibodies, immunisationwith the same antigen in a different
vector system was not protective. It remained unclear if the
protection was due to other antibody subclasses or cellular
immunity (Müller-Schollenberger et al. 2001). Conversely,
the use of recEg95 (in sheep) and recEm95 (in mice)
protected the animals against a challenge infection with
E. granulosus orE.multilocularis, respectively, and for both
vaccines, the protective immune correlate was based on
humoral immunity, i.e., appropriate antigen-specific
antibody levels (Gauci et al. 2002; Gauci et al. 2005).
In conclusion, our pilot study evidenced that vaccina-
tion of rhesus macaques with recombinant Em 14-3-3
antigen induces parasite-specific binding antibodies, with
alum being the most potent adjuvant in terms of antibody
levels and longevity. In order to evaluate the efficacy of the
immunisation regimen, a challenge infection of rhesus
monkeys vaccinated with the recombinant antigen is the
next logical step. In light of the increasing impact of alve-
olar echinococcosis on public health (Gottstein et al.
2015), the development of an effective prophylactic vacci-
nation against this zoonosis would be a great step forward
in the protection of animal and human health.
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